Contrast developer Bracco Diagnostics of Princeton, NJ, and group purchasing organization HealthTrust Purchasing Group of Brentwood, TN, have signed an agreement for Bracco's MRI contrast media products.
The three-year contract covers MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, and ProHance (gadoteridol) injection, 279.3 mg/mL.
HealthTrust supports more than 1,300 acute care hospitals, 430 ambulatory surgery centers, and more than 3,000 alternate care sites.
By AuntMinnie.com staff writers
October 8, 2007
Related Reading
Bracco, ImaRx sign licensing pact, July 4, 2007
VisualSonics, Bracco partner, June 8, 2006
Bracco opens perfusion PET company, June 1, 2006
Bracco inks Amerinet deal, January 26, 2006
Bracco to sell Esaote, January 23, 2006
Copyright © 2007 AuntMinnie.com
